Australia markets closed

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.2800+0.0300 (+2.40%)
At close: 04:00PM EDT
1.2200 -0.06 (-4.69%)
After hours: 06:17PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 31.84M
Enterprise value 20.07M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)255.50
Price/book (mrq)3.68
Enterprise value/revenue 138.33
Enterprise value/EBITDA -1.55

Trading information

Stock price history

Beta (5Y monthly) 0.48
52-week change 3-71.93%
S&P500 52-week change 322.55%
52-week high 35.3300
52-week low 31.2000
50-day moving average 32.3722
200-day moving average 33.1776

Share statistics

Avg vol (3-month) 3228.08k
Avg vol (10-day) 3748.72k
Shares outstanding 525.17M
Implied shares outstanding 625.17M
Float 816.83M
% held by insiders 16.76%
% held by institutions 111.07%
Shares short (14 June 2024) 4500.33k
Short ratio (14 June 2024) 41.7
Short % of float (14 June 2024) 42.97%
Short % of shares outstanding (14 June 2024) 42.77%
Shares short (prior month 15 May 2024) 4100.71k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-74.54%
Return on equity (ttm)-177.83%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -21.37M
Net income avi to common (ttm)-21.14M
Diluted EPS (ttm)-1.5000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.66M
Total cash per share (mrq)0.7
Total debt (mrq)889.62k
Total debt/equity (mrq)10.29%
Current ratio (mrq)2.77
Book value per share (mrq)0.48

Cash flow statement

Operating cash flow (ttm)-18.24M
Levered free cash flow (ttm)-10.24M